PharmaCielo (PCLOF)
OTHER OTC:PCLOF
PCLOF Stock Chart & Stats
$0.01
<$0.01(6.14%)
At close: 4:00 PM EST
$0.01
<$0.01(6.14%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.12
Previous CloseN/A
Volume1.75K
Average Volume (3M)9.90K
Market Cap
$9.89M
Enterprise Value$34.34M
Total Cash (Recent Filing)$289.24K
Total Debt (Recent Filing)$18.65M
Price to Earnings (P/E)―
Beta-1.89
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding187,983,690
10 Day Avg. Volume17,743
30 Day Avg. Volume9,897
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market Cap3.47
Enterprise Value/Revenue13.15
Enterprise Value/Gross Profit45.39
Enterprise Value/Ebitda-34.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Cannabinoid Supply ModelA focused B2B model selling standardized cannabinoid inputs to medical and wellness manufacturers supports recurring bulk orders and longer sales contracts versus retail. Institutional customers favor reliable suppliers, giving PharmaCielo durable demand if it maintains quality and regulatory compliance.
Vertical Cultivation And Processing CapabilitiesOwnership of cultivation and extraction assets creates vertical integration that can improve input quality control, reduce per-unit costs, and ensure supply reliability. Over time this supports margin expansion and customer retention versus pure-play resellers dependent on third-party suppliers.
Positive Product-level Gross MarginA ~29% gross margin indicates core production economics are viable at the product level. If management can stabilize volumes and reduce fixed-cost leverage, product margins provide a path to cover operating costs and move toward operating-profitability as scale and mix improve.
Bears Say
Declining And Volatile RevenueSustained top-line decline and volatility undermine the company’s ability to leverage its positive product margins. Weak revenue makes capacity utilization and long-term contracts harder to secure, limiting predictable cash generation and delaying any durable recovery in operating profitability.
Highly Leveraged Balance Sheet And Negative EquitySignificant negative equity and debt materially constrain financial flexibility. High leverage raises refinancing and solvency risk, reduces capacity for strategic investment, and increases the probability that future capital needs will be met via dilutive equity or onerous debt terms.
Persistent Cash Burn And Negative Free Cash FlowNegative operating and free cash flow means the business currently consumes cash to run operations. While cash outflows have improved from prior years, continued burn requires external funding for debt service or growth, creating execution risk and potential dilution until sustained positive cash generation occurs.
PharmaCielo News
PCLOF FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was <$0.01 and its highest was $0.12 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is $9.89M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is Aug 14, 2026 which is in 59 days.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 187,983,690 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in PCLOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medicinal products. Additionally, the company diversifies its offerings by providing telemedicine software. Its clientele spans a range of entities, such as health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, across both Canada and Colombia. PharmaCielo also holds a strategic partnership with AssuredTrans Inc., and its corporate headquarters are situated in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Ownership Overview
16.47% Insiders
0.16% Other Institutional Investors
83.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---